Hematologic Oncology

The demonstrated impact of imatinib mesylate on outcomes for patients with CML shifted the oncology paradigm to an intensive search for relevant molecular target.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Stephen Ansell, from the Mayo Clinic, on Treating Patients With Waldenström Macroglobulinemia

Discussion with Andrew D. Zelenetz, MD, PhD, on a number of new therapies and interesting challenges regarding the treatment of patients with both Hodgkin and non- Hodgkin lymphoma.

Dr. Harry Erba, from University of Michigan Health System, Discusses Molecular Monitoring for CML

Michael Eckenfels, RN, OCN, from MD Anderson Cancer Center, on Changes to the Bortezomib Delivery Route.

William G. Wierda, MD, PhD, discussed the management of chronic lymphocytic leukemia at the 16th Annual International Congress on Hematologic Malignancies.

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Treatment Options for DLBCL

Results of recent trials investigating novel therapies for chronic lymphocytic leukemia were discussed at the 16th Annual International Congress on Hematologic Malignancies.

The prognosis for a significant fraction of DLBCL patients that relapse while receiving the current standard treatment of R-CHOP-21 remains poor.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses Treatment Options for Primary Mediastinal B Cell Lymphoma

There are many ideas that if followed will not just help you to "do your time" during fellowship, but contribute to the internal medicine residency program.

There is no such thing as a typical day. Our days are punctuated by the unexpected and our field is so diverse that we often change what we do over the course of our careers. Time alters us and our field.

Elotuzumab demonstrated notable response rates as combination therapy in a phase II study of patients with relapsed or refractory multiple myeloma.

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Dr. Harry Erba, from the University of Michigan Health System, Discusses the Frontline Treatment of CML

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses ABC DLBCL Research

Continuous treatment with lenalidomide given early prolonged the time to progression, compared with no treatment in patients with high-risk, asymptomatic, smoldering, multiple myeloma.

ODAC voted 7-4 (2 abstentions) in support of vincristine sulfate liposomes injection to treat patients with Ph-negative ALL.

It may be possible to forgo radiation in previously untreated patients with limited-stage Hodgkin lymphoma.

Vorinostat added to bortezomib improved progression-free survival compared with bortezomib plus placebo in patients with relapsed/refractory multiple myeloma.

Dr. William Wierda, from the MD Anderson Cancer Center, Discusses Watchful Waiting in CLL

Treatment of selected cases of localized lymphoma during the second and third trimester was associated with minimal maternal and fetal risk of complications.

Dr. Sundar Jagannath, from Mount Sinai Medical Center, Discusses the VANTAGE Trials